Your shopping cart is currently empty

KARS-IN-1 (152) is an AKR1C3-dependent KARS inhibitor with an AC50 of 9.1 nM for human KARS. It exhibits antiproliferative activity in both H460 (NRF2 pathway-mutant cell line with high AKR1C3 expression) and Hara (NRF2 pathway wild-type cell line with low AKR1C3 expression), with AC50 values of 21 nM and 16 nM, respectively. KARS-IN-1 is applicable in non-small cell lung cancer (NSCLC) research.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | KARS-IN-1 (152) is an AKR1C3-dependent KARS inhibitor with an AC50 of 9.1 nM for human KARS. It exhibits antiproliferative activity in both H460 (NRF2 pathway-mutant cell line with high AKR1C3 expression) and Hara (NRF2 pathway wild-type cell line with low AKR1C3 expression), with AC50 values of 21 nM and 16 nM, respectively. KARS-IN-1 is applicable in non-small cell lung cancer (NSCLC) research. |
| Molecular Weight | 387.43 |
| Formula | C21H23F2N3O2 |
| Cas No. | 2579083-99-9 |
| Smiles | O[C@@H]1CC2(NC=3C1=CC(F)=CC3)CCN(C(NCC4=CC=C(F)C=C4)=O)CC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.